mappharma.com
域名年龄: 21年12天HTTP/1.0 302 Found 目标网址:http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=735125 服务器:BigIP 连接:Keep-Alive 文件大小:0 HTTP/1.1 200 OK 连接:关闭 访问时间:2015年04月03日 21:22:45 类型:text/html;charset=UTF-8 服务器:Microsoft-IIS/6.0 语言环境:ASP.NET 设置Cookie:AGN_SESSION=0%7C%20%7Bts%20%272015%2D04%2D03%2009%3A22%3A45%27%7D%7C%20%7Bts%20%272015%2D04%2D03%2009%3A22%3A45%27%7D%7CC88AA5E36D3720DB1EDCF05E5F6F85A0; Domain=agn.client.shareholder.com; Expires=Sat, 02-Apr-2016 13:22:45 GMT; Path=/; HttpOnly 设置Cookie:AGN_BRIEFCASE=UPDATED%7C42007%2E3907986; Domain=agn.client.shareholder.com; Expires=Sat, 02-Apr-2016 13:22:45 GMT; Path=/ 设置Cookie:AGN_PREVIEW=""; Expires=Thu, 01-Jan-1970 00:00:10 GMT; Path=/ Content-Encoding: gzip 动作:Accept-Encoding Transfer-Encoding: chunked 网站编码:UTF-8 页面编码:iso-8859-1
Skip to contentGlobal Locations Contact Us SearchAbout Us HistoryMission and ValuesGlobal LocationsWhat We TreatEye Care:Dry EyeGlaucomaOther Eye ConditionsNeurosciences :BlepharospasmCervical DystoniaChronic MigraineStrabismusUpper Limb SpasticityMedical Aesthetics :Breast AestheticsFacial AestheticsMedical Dermatology :AcnePsoriasisSevere Primary Axillary Hyperhidrosis Inadequately Managed with Topical AgentsOther Skin ConditionsUrologics :Urinary IncontinenceOveractive BladderProducts Ophthalmic PharmaceuticalsNeurosciencesMedical Aesthetics: Breast and FacialMedical DermatologyUrologicsProduct Prescribing and Labeling InformationPatent NoticesR&DAllergan Clinical TrialsExcellence in ResearchMedical AffairsNewsroomPress ReleasesInvestorsFinancial ReportsCorporate Governance & CertificatesContact InformationResponsibility Corporate Social ResponsibilityPatient Safety and Product QualityCompliance and EthicsAllergan FoundationPatient ResourcesPhysician ResourcesProfessional AffiliationsUnrestricted Educational GrantsPolitical ContributionsCalifornia Supply Chain DisclosureHealth Care Provider Partnerships & PaymentsCommitment to Human Rights ChartersAnimal TestingCareers Mission and ValuesTotal RewardsRecognizing ExcellenceGlobal Careers at AllerganJob SearchMy Candidate ProfileFAQ-->-->-->-->In this Section:OverviewPress Releases201520142013201220112010 2009 2008 2007 2006 2005 ArchivesRelated Links:Corporate OverviewAllergan, Inc. to Acquire MAP Pharmaceuticals, Inc.Acquisition Enhances Allergan Leadership Position in Neurology andMigraine SpecialtyIRVINE, Calif. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE:AGN) and MAP Pharmaceuticals, Inc. (Nasdaq: MAPP)today jointly announced that they have entered into a definitive mergeragreement whereby Allergan will acquire 100% of the shares of MAPPharmaceuticals for a price of $25.00 per share. MAP Pharmaceuticals isa biopharmaceutical company focused on developing and commercializingnew therapies in Neurology, including LEVADEX®, an orally inhaled drugfor the potential acute treatment of migraine in adults. LEVADEX® iscurrently under review with the U.S. Food and Drug Administration (FDA).The transaction, which has been unanimously approved by the boards ofdirectors of both companies, will be accomplished pursuant to a cashtender offer followed by a second step merger. The per share cash offerprice represents a 60% premium over MAP's closing stock price on theNasdaq Stock Market of $15.58 on January 22, 2013, and represents atotal equity value of approximately $958 million, on a fully-dilutedbasis. The acquisition is expected to close late in the first quarter orin the second quarter of 2013."One of the key drivers of Allergan's continued success is our focus onmedical specialties where we have extensive knowledge of physician andpatient needs, and can provide a broad portfolio of products,
© 2010 - 2020 网站综合信息查询 同IP网站查询 相关类似网站查询 网站备案查询网站地图 最新查询 最近更新 优秀网站 热门网站 全部网站 同IP查询 备案查询
2025-01-29 21:52, Process in 0.0056 second.